Intelligence

Industrials

BioLargo Achieves Record Revenues in 2024 Annual Report

Author:
FAQsIR News Desk
Last Updated:
Reading Time
2 min

#Record Revenue Growth for BioLargo

BioLargo, Inc. has reported a remarkable revenue growth of 45% for the year ending December 31, 2024. This achievement marks the company's tenth consecutive year of increasing revenues, with total sales reaching approximately $17.8 million. The announcement was made in the company's recent Annual Report, filed with the Securities and Exchange Commission (SEC).

#Financial Overview

Despite the significant revenue boost, BioLargo recorded a net loss of $4.3 million for the year, which shows a 6% decrease compared to the previous year. This loss was primarily attributed to the operational costs associated with Clyra Medical, responsible for a substantial portion of the company's expenses.

Notably, the company reported generating over $5 million from its odor control products, which has helped in reducing its reliance on equity financing. BioLargo issued 42% fewer shares in 2024 compared to 2023, indicating a strategic shift towards improved cash flow management.

#Product Developments

BioLargo's annual report highlighted progress in its product offerings, particularly with Clyra Medical's surgical irrigation solutions. The company is moving closer to a national rollout, having recently completed a successful joint inspection of manufacturing capabilities with its distribution partner. These advancements are poised to enhance BioLargo's position in the medical technology market.

The company is also focusing on resolving significant environmental challenges with its innovative products aimed at tackling the global PFAS contamination crisis and introducing long-lasting battery energy storage technology known as Cellinity.

#Financial Position and Future Outlook

As of December 31, 2024, BioLargo's stockholders' equity stood at $6.06 million, with total assets of $10.51 million against liabilities of $4.46 million. The company also maintained $3.55 million in cash and cash equivalents, providing a solid foundation for its operational activities and growth initiatives in the upcoming year.

Moving forward, stakeholders are encouraged to take note of the potential risks outlined in the SEC filings, which may impact the company's performance amidst a competitive environment in the cleantech sector.

#Key Takeaways

  • BioLargo achieved a record revenue of $17.78 million in 2024, marking a 45% increase year-over-year.
  • The company recorded a net loss of $4.35 million, a reduction of 6% from the previous year.
  • BioLargo has reduced equity financing reliance by issuing 42% fewer shares than in 2023.
  • Clyra Medical is advancing its surgical products toward national distribution, reflecting growth potential in healthcare.
  • The company emphasizes innovation in tackling environmental issues through its product development.

Original source: Read original article

Frequently Asked Questions

BioLargo reported record revenues of $17.78 million for the year ended December 31, 2024, reflecting a robust 45% increase over the prior year. This marks the tenth consecutive year of revenue growth, demonstrating the company's sustained market traction and resilience.
In 2024, BioLargo successfully generated over $5 million from its odor control products, allowing for a 42% reduction in stock issuance compared to 2023. This strategic shift may indicate improved cash flow management and operational efficiency.
Clyra Medical is progressing towards a national rollout of its surgical irrigation products, reflecting its commitment to innovation in healthcare technology. The recent successful inspection of manufacturing capabilities suggests readiness for market expansion.
BioLargo's net loss of $4.35 million in 2024, a decrease of 6% year-over-year, highlights ongoing investments in growth and development. The majority of this loss stemmed from Clyra Medical, indicating a focus on future profitability as products gain market traction.
As of December 31, 2024, BioLargo maintained a solid cash position with $3.55 million in cash and cash equivalents, along with $4.49 million in working capital. This financial foundation provides a buffer for ongoing operational activities and potential growth initiatives.
With a diverse portfolio addressing critical environmental and health challenges, including PFAS contamination and energy storage solutions, BioLargo is well-positioned for future growth. Its focus on innovative technologies underpins its potential for expanding market reach.
BioLargo's stockholders' equity was reported at $6.06 million at the end of 2024, reflecting a stable financial structure. This aligns with the company’s efforts to reduce reliance on external financing and improve its overall financial health.
While BioLargo shows potential for growth, investors should also be mindful of the risks outlined in its SEC filings, including competition and market dynamics. A thorough examination of these factors, alongside the company's growth trajectory, can provide deeper insights for informed investment decisions.